Data / Form D filings / Diceros Therapeutics, Inc.
Diceros Therapeutics, Inc.: Form D filings
Diceros Therapeutics, Inc., a biotechnology company in Newton, MA, filed 2 Form D notices with the SEC between 2022 and 2024. The latest, on August 5, 2024, reports $12.6 million sold of a $18.1 million offering to 13 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 275 GROVE STREET, 2-400, Newton, MA, 02466
- Phone
- (617) 663-5784
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1948469
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 5, 2024 | Amendment | $18,069,960 | $12,609,962 | $5,459,998 | 13 | Sep 19, 2022 | sec.gov |
| Sep 30, 2022 | New notice | $16,699,979 | $6,679,992 | $10,019,987 | 13 | Sep 19, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stephen R. Seiler | Executive Officer, Director | |
| Ids R. van der Weij | Director | |
| Wyatt R. Gotbetter | Director | |
| Jonathan R. Fleming | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Aug 5, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Diceros Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.